Please select the option that best describes you:
Do you continue somatostatin analogs beyond progression to maintain disease control in low-intermediate grade neuroendocrine tumors?
If so, are there particular patient/tumor characteristics that influence your decision?
Answer from: Medical Oncologist at Academic Institution
Unfortunately there is no clear data on whether to continue somatostatin analogues (SSA) upon progression in NETs. Certainly for a functional tumor (ie carcinoid syndrome) it makes perfect sense to continue an SSA.An exception to continuing SSA upon progression is considered when we examine the NETT...
Sign in or Register to read more